Cargando…

Review article: role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know

BACKGROUND: Non‐alcoholic steatohepatitis (NASH) is characterised by hepatic lipid accumulation, cell injury, inflammation and fibrosis. Insulin resistance, a hallmark of type 2 diabetes (T2D) and obesity, is a key pathogenic driver of NASH. Other than difficult‐to‐maintain lifestyle changes, there...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barritt, A. Sidney, Marshman, Emma, Noureddin, Mazen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310586/ https://www.ncbi.nlm.nih.gov/pubmed/35266164 http://dx.doi.org/10.1111/apt.16794

Ejemplares similares

What hepatologists need to know about COVID-19?
por: Yapali, Suna
Publicado: (2020)

The liver in times of COVID-19: What hepatologists should know
por: Ridruejo, Ezequiel, et al.
Publicado: (2020)

Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article
por: Ghazanfar, Haider, et al.
Publicado: (2021)

Effect of COVID-19 on Pre-existing Liver disease: What Hepatologist Should Know?
por: Sharma, Praveen, et al.
Publicado: (2021)

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
por: Armstrong, Matthew J., et al.
Publicado: (2016)

Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know
por: Skolnik, Neil, et al.
Publicado: (2018)

Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist?
por: Khandelwal, Reshu, et al.
Publicado: (2021)

Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey
por: Rinella, Mary, et al.
Publicado: (2022)

Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge
por: Steggerda, Justin A, et al.
Publicado: (2020)

Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
por: Noureddin, Mazen, et al.
Publicado: (2019)

Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis
por: Xue, Huan, et al.
Publicado: (2023)

Exercise and Alcohol Consumption: What We Know, What We Need to Know, and Why it is Important
por: Leasure, J. Leigh, et al.
Publicado: (2015)

Drug and Alcohol Abuse: What Physicians Need to Know
por: Bradberry, Sally M
Publicado: (2000)

Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis
por: Nestor, John J., et al.
Publicado: (2022)

Gastroenterologists, Hepatologists, COVID-19 and the Use of Acetaminophen
por: Rodríguez-Morales, Alfonso J., et al.
Publicado: (2020)

Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis
por: Kojima, Motoyasu, et al.
Publicado: (2020)

‘Need-to-Know’ emergency medicine articles of 2014
por: Huis in ‘t Veld, Maite A, et al.
Publicado: (2015)

Spectrum of MRI findings of foetal alcohol syndrome disorders—what we know and what we need to know!
por: Sharif, Saad, et al.
Publicado: (2023)

Practice Habits, Knowledge, and Attitudes of Hepatologists to Alcohol Use Disorder Medication: Sobering Gaps and Opportunities
por: Cotter, Thomas G., et al.
Publicado: (2020)

Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass?
por: Noureddin, Nabil, et al.
Publicado: (2020)

Non-inferiority trials in cardiology: what clinicians need to know
por: Leung, James T, et al.
Publicado: (2020)

Factors influencing the participation of gastroenterologists and hepatologists in clinical research
por: Dev, Anouk T, et al.
Publicado: (2008)

Advancing health equity: The Association of Black Gastroenterologists and Hepatologists
por: White, Pascale M., et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease in Diabetics: The Role of Hepatologist
por: Khandelwal, Reshu, et al.
Publicado: (2022)

Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis
por: Yokomori, Hiroaki, et al.
Publicado: (2020)

What you need to know
por: Le Page, Michael, et al.
Publicado: (2020)

Epigenetics in Schistosomes: What We Know and What We Need Know
por: Liu, Weiwei
Publicado: (2016)

Portion Size: What We Know and What We Need to Know
por: Benton, David
Publicado: (2015)

Paediatric schistosomiasis: What we know and what we need to know
por: Osakunor, Derick N. M., et al.
Publicado: (2018)

Metabolic syndrome: what we know and what we need to know
por: Soares, Raquel
Publicado: (2020)

Moving Toward Impact: An Introduction to Implementation Science for Gastroenterologists and Hepatologists
por: Rogal, Shari S., et al.
Publicado: (2020)

Barriers to research productivity among gastroenterologists and hepatologists in Saudi Arabia
por: AlSardi, Mais, et al.
Publicado: (2020)

COVID-19-associated liver injury (COVALI): role of hepatologists
por: Sumida, Yoshio, et al.
Publicado: (2021)

The glucagon‐like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents
por: Vallöf, Daniel, et al.
Publicado: (2015)

Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
por: Sofogianni, Areti, et al.
Publicado: (2020)

Radiation: what it is, what you need to know
por: Gale, Robert Peter, et al.
Publicado: (2013)

Nephrotoxicity testing in vitro--what we know and what we need to know.
por: Pfaller, W, et al.
Publicado: (1998)

Goal-directed therapy: what we know and what we need to know
por: O’Neal, Jason B, et al.
Publicado: (2015)

Membrane fission by dynamin: what we know and what we need to know
por: Antonny, Bruno, et al.
Publicado: (2016)

Microplastics in freshwater ecosystems: what we know and what we need to know
por: Wagner, Martin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mtrcr0tmmg0pb5d68ripn5fbdt